Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sunedison : NRG closes on 1.5GW SunEdison portfolio of PV/wind projects
11/24/2016 | 09:14am EST
NRG announced Wednesday that is has closed on its acquisition of all projects within a 1.5GW portfolio of SunEdison installations.
The portfolio is comprised of more than 1.5GW of utility-scale PV and wind projects that are either completed or in varying stages of development across the United States.
As part of a separate deal with SunEdison, NRG also closed on the acquisition of 29MW of distributed generation and community solar projects that are under development across 26 sites in several states.
Together, the acquisitions will help NRG increase the capabilities of its cross-functional platform into many markets that it already serves, such as California, Texas and Massachusetts.
The deal will also allow NRG to enter into new markets for utility-scale solar projects, including Hawaii and Utah. Nearly 265MW of the portfolio is now online and operational, increasing the NRG operating renewables portfolio to nearly 4.7GW across 26 states.
Assets in the portfolio include a partnership interest in a 530MW fully-constructed pipeline of seven utility-scale solar projects in Utah and the ownership of a partially constructed solar plant in Texas.
Other facets of the portfolio include the ownership of 1.1GW of solar and wind assets in various stages of development across the U.S., including 111MW of construction-ready assets in Hawaii as well as 17MW of projects across 21 sites for municipal and education counterparties in California, Florida, Massachusetts and Connecticut that are expected to be operational by early 2017.
http://www.4-traders.com/SUNEDISON-INC-27471608/news/Sunedison-NRG-closes-on-1-5GW-SunEdison-portfolio-of-PV-wind-projects-23456129/
Sunedison : School district buys into solar
11/23/2016 | 05:15am EST
Mankato Area Public Schools is buying a solar energy subscription that is expected to save the district over $6 million over the next 25 years.
The Mankato School Board on Monday approved a contract with SunEdison to, in effect, purchase solar power from two of its planned area community solar gardens.
The district will pay a fixed rate for the solar electricity a rate that is lower than it presently pays to Xcel Energy.
The contract duration is 25 years with opt-out options after 15 and 20 years if the district isn`t getting its promised savings.
The solar subscription is for the majority of district buildings powered by Xcel Energy. Three of the district`s secondary schools are served by BENCO Electric and aren`t part of the deal, according to Director of Business Affairs Jerry Kolander.
SunEdison is planning to build two solar arrays, one near Eagle Lake and one near Courtland. The gardens will be built sometime next year; Kolander did not know a precise date. The district will start reaping savings as soon as the gardens are operational, Kolander said.
The energy produced at the future gardens will be added to Xcel`s grid.
Instead of paying Xcel, the school district will pay SunEdison11.5 cents per kilowatt hour for the Xcel electricity it uses. The rate won`t change while Xcel`s rates are expected to increase.
Our offer is designed to save money today while protecting against long-term energy price volatility and increases, SunEdison Senior Director of Community Solar Pete Giese wrote in a proposal to the district. By providing Mankato Area Public Schools with a flat rate for energy, the offer SunEdison has designed provides an extremely valuable hedge against Xcel rate increases.
The district`s annual Xcel bill is over $630,000. The SunEdison proposal projected a first-year savings of $34,000. A $2.4 million savings is projected over 15 years and a nearly $6.4 million savings is projected over 25 years. Those projections assume Xcel rates increase 4 percent the next few years and 2.8 percent a year thereafter.
The district has spent nearly two years thoroughly vetting the proposal, according to Kolander.
Kolander said attorneys for the district have looked into the fact the global renewable energy conglomerate has filed for bankruptcy and found it shouldn`t affect the solvency of the local solar array plans.
School Board member Abdi Sabrie inquired whether district leaders have considered installing solar panels on school roofs. Kolander responded it has been considered and found to have drawbacks. Leaders will revisit the idea as solar energy technology evolves, he added.
School Board member Sara Hansen said she supported joining community solar gardens as a less risky way of investing in renewable energy.
Blue Earth County and the city of Mankato recently entered into similar solar subscriptions.
The county approved the same fixed rate contract with SunEdison in March. If Xcel rates rise an average of 2 percent a year, the subscription will save the county $1.2 million over 25 years.
The city is partnering with a different solar developer, Geronimo, which also is planning two solar gardens in the area. The city will receive a penny per kilowatt-hour discount on Xcel`s rate, yielding an estimated $1.6 million savings over 25 years
http://www.4-traders.com/SUNEDISON-INC-27471608/news/Sunedison-School-district-buys-into-solar-23449002/
SUNEQ, follow the path of BTUUQ? Maybe, yes!
Brookfield Asset proposes to take 50-60 percent stake in TerraForm Power
http://www.reuters.com/article/us-brookfield-asset-terraform-power-idUSKBN13D1QQ
Brookfield says prepared to make $13/share offer for TerraForm Power
Nov. 18, 2016 9:55 AM ET|About: TerraForm Power, Inc. (TERP)|By: Carl Surran, SA News Editor
TerraForm Power (TERP +4.4%) pops higher at the open after Brookfield Asset Management (BAM +0.2%) affirms a 12.1% active stake in the company, proposes to pay $13/share for a 50%-60% stake and says it is prepared to make an offer for TerraForm Global (GLBL +4%).
BAM also offers to act as interim sponsor of the TerraForm companies for a period of up to six months.
BAM, which in June expressed interest in buying SunEdison's (OTCPK:SUNEQ) stake in TERP, said last week it had met with the companies and their advisers to discuss options for a deal.
http://seekingalpha.com/news/3225774-brookfield-says-prepared-make-13-share-offer-terraform-power
SUNEQ, follow the path of BTUUQ? Maybe, yes! ;)
$5.50 price target. Shares Rally Following Ladenburg Upgrade To Buy, Positive Data
Shares of Repros Therapeutics Inc
RPRX 2.34%
climbed more than 8 percent in Wednesday’s pre-market hours after positive clinical data of Proellex led Ladenburg Thalmann to upgrade shares to Buy, with a $5.50 price target.
Repros announced positive Phase 2b data for both its oral and vaginal delivery trials following two 18-week cycles of treatment with Proellex in uterine fibroids.
Among others, the study met its primary endpoint of induction of amenorrhea for both pooled oral and vaginal delivery compared to placebo. The company plans to submit a request to the FDA before the end of 2016 to discuss the Phase 3 program......
http://www.benzinga.com/analyst-ratings/analyst-color/16/11/8707546/repros-therapeutics-shares-rally-following-ladenburg-upg
The Cannabis Industry Hopeful After Elections
NEW YORK, November 11, 2016 /PRNewswire/ --
http://www.Financialbuzz.com - According to ArcView Market Research, the legal cannabis market will see a whopping $21.8 billion in total annual sales by 2020. The market is expected to grow at a compound annual growth rate of nearly 30% over the next few years. Voters this past week in California, Massachusetts, Nevada and Maine decided that recreational cannabis is now legal. New Age Farm Inc. (OTC: NWGFF), MCig Inc. (OTC: MCIG), Terra Tech Corp. (OTC: TRTC), Medical Marijuana Inc. (OTC: MJNA), Growblox Sciences Inc. (OTC: GBLX).
Whether you have bad or good thoughts about the election results, it was a good year for thus far for the cannabis industry. California, Massachusetts and Nevada and Maine legalized marijuana on this past week. These major states could be the reflection of the country's changing opinions toward cannabis, both for medical and recreational purposes. Now more than 20 percent of Americans can use cannabis or marijuana legally.
New Age Farm Inc. (OTC: NWGFF) offers a unique growing infrastructure and services for licensed growers and processors of luxury crops including cannabis at their green campuses in Washington State and British Columbia. Two campuses in Washington State - one in Sumas and one in Oroville - are capable of welcoming specialty producers as well as licensed marijuana growers.
New Age Farm Inc. announced that it will implement the Plan of Arrangement with its wholly owned subsidiary, NHS Industries Ltd. ("NHS") approved by the Company's shareholders at its AGM (see News Releases dated September 22 and 30, 2016). The Company will prepare NHS facilities and infrastructure in Langley, BC in anticipation of Canada's recreational marijuana industry.
New Age Farm Inc. Plan of Arrangement - New Age Farm and NHS entered into an arrangement agreement effective August 31, 2016 whereby New Age Farm would spin-off NHS, together with all its assets and liabilities, as a separate operating entity and NHS would operate the Company's Langley Property located in Langley, British Columbia (the "Arrangement"). In return, following completion of the Arrangement, Shareholders would hold one new share (each, a "New Share", collectively the "New Shares") in the capital of the Company and its pro-rata share of the post-consolidation NHS Shares to be distributed under the Arrangement for each currently held New Age Farm share. The New Shares would be identical in every respect to the present New Age Farm shares.
New Age Farm Inc. Share Distribution Record Date - The board of directors of New Age Farm have set the share distribution record date of the Plan of Arrangement at close of business on November 30, 2016 (the "Share Distribution Record Date"). Shareholders as of the Share Distribution Record Date will be entitled to receive the New Shares and the NHS Shares. Each shareholder of record on November 30, 2016 will participate in the Arrangement on a pro-rata basis and, upon completion of the Arrangement, will continue to hold substantially the same pro-rata interest they held in the Company prior to completion of the Arrangement. The New Shares will be identical in every respect to the shareholders' current New Age Farm shares; in addition, each New Age Farm shareholder will receive from NHS the number of common shares equal to the issued and outstanding common shares of New Age Farm held by the shareholder as of the Share Distribution Record Date, divided by an exchange ratio. The Arrangement was unanimously approved by the Shareholders at the AGM, and remains subject to final approval from applicable regulators. The Company provided full details of the Arrangement in an information circular that was mailed to the Shareholders and is available on SEDAR (the "Circular").
MCig Inc. (OTCQB: MCIG) released a research report and analysis by Technical 420, LLC, which provides a view of the company, its product offerings and target markets. The report is available at Research Report that was conducted by Technical 420's founder Michael Berger. MCIG's Chief Financial Officer, Mike Hawkins stated, "The Company wanted to have an evaluation done as a way to measure strengths and potential areas for improvement. More importantly, we wanted a high caliber point of view that comes from public data and numbers crunching. The Company has made the report available on its website for the convenience of the shareholders as a means to reference the information with their own point of view." The CFO went on to state, "MCIG continues its growth in the cannabis markets and we feel we are well positioned based on company fundamentals and pristine capital structure."
Medical Marijuana Inc. (OTC: MJNA) products focuses on cannabidiol hemp oil, a legal extract from cultivated hemp plants, that is non-psychoactive, contains a full spectrum of phytocannabinoids, and is high in CBD. Through its subsidiaries, HempMeds® and Kannaway®, their businesses focuses on consumer product distribution and has been able to provide hemp oils featuring high CBD to over 200,000 people. Its entire "CBD pipeline" products are free of herbicides, pesticides, or any harmful chemical fertilizers.
Terra Tech Corp. (OTCQX: TRTC) is a cannabis-focused agriculture company. The Company operates through two segments: Hydroponic Produce and Cannabis Products. The Company, through its subsidiary, GrowOp Technology Ltd., is engaged in the design, marketing and sale of hydroponic equipment. It is also a retail seller of locally grown hydroponic produce, herbs, and floral products through its subsidiary, Edible Garden Corporation. Through its subsidiary, IVXX Inc., it produces and sells a line of cannabis flowers and cigarettes, among others. The hydroponic produce segment consists of Edible Garden's business and operations. Its cannabis products segment consists of IVXX's business, as well as the proposed business operations of MediFarm, MediFarm I and MediFarm II.
Growblox Sciences Inc. (OTCQB: GBLX) has established its proprietary GrowBLOX™ technology suite to control the growth of Cannabis and other plants with high medicinal value to a pharmaceutical-industry quality standard. The GrowBLOX™ system allows the company to create "GBLX" branded, patented and certified therapeutic mixtures of raw plant ingredients through a comprehensive GBLX Quality Management Program. GB Sciences acts as the central hub for testing the GBLX-certified materials in a technologically data-driven biopharmaceutical innovation system to produce and authorize novel cannabis-based therapies for patients with clinically unmet requests.
http://www.prnewswire.com/news-releases/the-cannabis-industry-hopeful-after-elections-600813611.html
More Recreational Marijuana Helps This Small Cap
On Tuesday, voters in California, Maine, Massachusetts and Nevada passed measures to legalize recreational marijuana – good news for more well known marijuana stocks like GW Pharmaceuticals PLC (NASDAQ: GWPH) and Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA), but especially for small cap Lexaria Bioscience Corp (OTCQB: LXRP).
http://www.smallcapnetwork.com/More-Recreational-Marijuana-Helps-This-Small-Cap/s/via/52883/article/view/p/mid/1/id/173/
KTOS had its "buy" rating reaffirmed by analysts at B. Riley. They now have a $9.00 price target on the stock.62.5% Upside
https://www.marketbeat.com/ratingsdb/details/728831/ …
X to Post Q3 2016 Earnings of $1.11 Per Share, KeyCorp Forecasts (X)
https://www.thecerbatgem.com/2016/10/28/united-states-steel-corp-to-post-q3-2016-earnings-of-1-11-per-share-keycorp-forecasts-x.html
(X) Given Consensus Rating of “Hold” by Analysts
http://www.com-unik.info/2016/10/24/united-states-steel-corp-x-given-consensus-rating-of-hold-by-analysts.html
(NASDAQ:CERU) had its "buy" rating reaffirmed by analysts at Roth Capital. They now have a $2.50 price target on the stock. 164.7% upside from the previous close of $0.94.
http://www.americanbankingnews.com/2016/10/23/cerulean-pharma-inc-ceru-given-buy-rating-at-roth-capital.html
Ratings Breakdown:
3 Hold Ratings, 5 Buy Ratings
Consensus Rating:
Buy (Score: 2.63)
Consensus Price Target:
$8.63 (1,041.02% upside)
https://www.marketbeat.com/stocks/NASDAQ/CERU/
Patience!
Goodyear Tire & Rubber : Vienna notes business anniversaries
10/10/2016 | 11:25am EDT
The Vienna town government recently announced the following business anniversaries in town:
50 Years: Goodyear Tire & Rubber Co.
20 Years: Breakthrough Achievements; PCS Heating and Air Conditioning; Westwood Tennis.
15 Years: Allegiance Financial Group; Jammin' Java; Shillelagh Travel Club.
© Fairfax Sun Gazette © Copyright 2016, Sun Gazette Newspapers, Springfield, VA., source Newspapers
http://www.4-traders.com/GOODYEAR-TIRE-RUBBER-CO-12202146/news/Goodyear-Tire-Rubber-Vienna-notes-business-anniversaries-23191248/
ROHAN MARLEY, You do not seem son of Bob Marley. Big Rat!!!
I still think the company is sold.
There is much fear in the markets. It is the worst enemy, because anything can happen.
You have to be patient.
A good investment, ABEO $6.45
You enter, when the time
http://stockcharts.com/h-sc/ui?s=ABEO
Why? It is the same case as Bill Gates with Microsoft.
He resigned as CEO, but remains the majority shareholder
It´s right. You have any idea how much money does the name Marley?
Someone thinks that the son of the great Bob Marley, swindle the investors?
https://investor.marleycoffee.com/
National Coffee Day arrives as prices march higher
Sep 29 2016, 10:02 ET | By: Clark Schultz, SA News Editor
It's National Coffee Day in the U.S., but it's weather in Brazil and Vietnam that is the focus of the coffee industry.
Drought conditions and crop disease concerns have pushed prices higher and created some short-term supply constraints.
Indexmundi.com shows robusta coffee prices are up 18% YTD and mild arabicas prices are 16% higher.
Higher commodity prices can hit packaged coffee sellers harder than chains selling fresh coffee, although hedging activity also plays a larger factor in how individual companies shake out.
On a consumer level, don't expect any relief at Starbucks on their base coffee prices ($1.85 tall, $2.10 grande, $2.45 venti) anytime soon.
Related tickers: SBUX, DNKN, SJM, QSR, MCD, MDLZ, KKD, WWAV, JVA, OTCQB:JAMN, OTCQB:BCCI, FARM, OTCPK:NSRGY.
ETFs: JO, CAFE.
http://seekingalpha.com/news/3211543-national-coffee-day-arrives-prices-march-higher
they are buying, that's important.
Zacks: Earnings change date for the 10/03/16
He went down to 2,032,601 shares
That's right, but if you buy at good prices, balance your previous price. In my opinion, I think the company is sold, it is a matter of time and patience.
In this business you have to have three things, money, eggs and patience.
At least, eggs and patience! ;)
VERY LITTLE VOLUME. 1,784,331 shares .
I think they are waiting for news. ??
Patience! ??
I THINK IT MAY END WELL, EVEN WITH THE SALE OF DE COMPANY !??
Consensus recommendation: HOLD (Financial Time)
As of Sep 16, 2016, the investment analyst covering Jammin Java Corp advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Nov 22, 2015. The previous consensus forecast advised that Jammin Java Corp would outperform the market.
http://markets.ft.com/data/equities/tearsheet/forecasts?s=JAMN:QBB
Zacks, Exp. Earnings Date 9/26/16 Buying back shares?
https://www.zacks.com/stock/quote/JAMN?q=JAMN
Jammin Java : Marley Coffee company up for sale. Opinions!
09/01/2016 | 12:00am EDT
JAMMIN JAVA Corp will seek to sell the coffee company if its countersuit against former chairman Rohan Marley and push to regain licensing control of the Marley Coffee name fail.
Marley stepped down as chairman of Jammin Java last month amid a dispute. The company trades as Marley Coffee.
Following his departure, the Marley familyowned entity, 56 Hope Road, announced it would terminate its short-term licence agreement with US-based Jammin Java, in essence denying the company the right to use the Marley Coffee name.
The stock now trades at a penny, down from a dime in June and US 14 cents in March.
"The only time Jammin Java has heard from Rohan in the last month was when I countersued," said CEO Brent Toev. "It makes me sick."
Toevs spent five years as CEO growing the brand from essentially nil to US$13 million in annual revenues. Toevs said he was on the cusp of raising millions of dollars through an investment firm SCB Investments, which would have received an equity stake in the company. That fell through with the pulling of the licence, Toevs explained. Since that time, sales have slowed, creditors are unpaid and the company started staff layoffs.
"There is [sic] huge damages involved. Before the licence was terminated, Jammin Java was valued at nine cents per share, but is now valued at US$0.01 a share," he said.
The Gleaner tried without success to contact Rohan Marley for comment.
NON-DISCLOSURE AGREEMENT
The brand obtained entry into 12,000 grocery stores in North America for more than many competitors. It wants to use this as retail real estate to offer to prospective buyers of the company.
"So we have brought in some people to look at the company who signed non-disclosure agreements for a possible buyout of the biz. But they need the Marleys to offer a long-term licensing agreement," he said.
Last week, Toevs issued a statement to shareholders indicating that the company might file for bankruptcy if issues with 56 Hope Road are unresolved.
In early August, 56 Hope Road filed a complaint against Jammin Java in a California court, and requested a temporary restraining order.
"We also filed our answer to the complaint and asserted counterclaims against 56 HR and thirdparty claims against Rohan Marley. We believe that our claims have merit and that we will be successful in the litigation," stated Toevs in the statement.
STEVEN JACKSON
Senior Business Reporter
Copyright The Gleaner Company Sep 1-Sep 7, 2016, source Newspapers
http://www.4-traders.com/JAMMIN-JAVA-CORP-6758458/news/Jammin-Java-Marley-Coffee-company-up-for-sale-23076967/
Stock Update (NYSEMKT:MSTX): Here’s Why Shares Crashed 84%
Corey Williams — September 20, 2016, 6:00 PM EDT
Tuesday turned out to be a nightmare for shareholders of Mast Therapeutics Inc (NYSEMKT:MSTX), as the biotech company disclosed that its Phase 3 clinical study of its investigational new drug vepoloxamer (also known as MST-188) for the treatment of individuals with sickle cell disease experiencing vaso-occlusive crisis (VOC) did not meet its primary efficacy endpoint of demonstrating a statistically significant reduction in the mean duration of VOC (82 hours in the vepoloxamer group compared to 78 hours in the placebo group in the intent-to-treat population (p=0.09)).
There were no statistically significant differences between treatment groups in the intent-to-treat population across the two secondary efficacy endpoints, rate of re-hospitalization for VOC and the occurrence of acute chest syndrome. Consistent with previously conducted studies, vepoloxamer was generally well tolerated with no statistically significant differences in treatment-related serious adverse events in the vepoloxamer group compared to the placebo group. No deaths occurred on the study.
Mast Therapeutics shares reacted to the disappointing news, crashing nearly 84% to $0.093 in after-hours trading.
“We are exceedingly disappointed with these top-line results. While clearly not the outcome we wanted, we believe the insights and data from the largest placebo-controlled clinical trial ever completed in sickle cell disease will substantially advance the understanding of vaso-occlusive crisis and the still maturing clinical science necessary to support the development of new therapeutics for this debilitating disease,” statedBrian M. Culley, the Company’s Chief Executive Officer. “We wish to reiterate our sincere appreciation for all of the patients, caregivers, and others who aided us in conducting this informative study.”
“These analyses are limited to just top-line data, so in the coming weeks the Company intends to review the full data set from EPIC. In addition, we plan to perform an interim analysis of the ongoing heart failure trial of vepoloxamer. However, based on the data we’ve seen to date, we expect we will terminate all clinical development of vepoloxamer. Consequently, while we evaluate our options, we intend to significantly and immediately reduce our operating expenses and continue our efforts with AIR001, our lead asset in heart failure with preserved ejection fraction, which currently is the subject of a 100-patient phase 2 study expected to complete enrollment by the end of 2017,” continued Mr. Culley. (Original Source)
On the ratings front, MSTX stock has been the subject of a number of recent research reports. In a report issued on September 12, Maxim analyst Jason McCarthy reiterated a Buy rating on MSTX, with a price target of $5.00, which represents a potential upside of 747.5% from where the stock closed today. Separately, on August 2, Roth Capital’s Michael Higgins reiterated a Buy rating on the stock and has a price target of $2.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason McCarthy and Michael Higgins have a total average return of 1.6% and 1.4% respectively. McCarthy has a success rate of 43% and is ranked #1472 out of 4166 analysts, while Higgins has a success rate of 51% and is ranked #1781.
Mast Therapeutics is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It provides products MST-188 has cytoprotective and hemorheologic properties and inhibits inflammatory processes and thrombosis.
http://www.smarteranalyst.com/2016/09/20/stock-update-nysemktmstx-heres-mast-therapeutics-inc-shares-crashed-84/
That is very bad news after hours. So is this business. Now we must take advantage of this.
MSTX, played dirty to say the news out of time, that means they knew the problem. BIG RATS!
Mast Therapeutics (MSTX) Stock: A Defining Moment Is Just Around The Corner.
Sep 20, 2016
Why Investors Have Mixed Opinions With Regard To The MSTX Study
We all know that Mast Therapeutics is working on a treatment known as Vexolaxamer. At the moment, the company is looking over the results of the EPIC trial, and should be releasing those results relatively soon. These results are overwhelmingly important. After all, if the results of the EPIC trial are positive, MSTX will have a new treatment that's tremendously close to reaching the market. However, if things go bad, the company will have spent massive amounts of time and money on a failed product. To add insult to injury, the company would have to pay back $10 million in loans immediately if the results missed the primary endpoint. So, with so much on the line, there are definitely going to be strong opinions on both sides.
There's also a bit more to the mixed opinions surrounding MSTX. You see, if the results were released in a timely manner, the bears would have been relatively silent in the process. However, the results haven't been released. In fact, they are months late. Because of this, some investors believe that the results will be overwhelmingly negative and that now is the time to get rid of the stock.
What I Think We'll See
First off, I have to say, the bearish view is definitely understandable. Mast Therapeutics should have released the study data quite a while ago, and the delays are becoming overwhelmingly concerning. However, I don't believe that the release of the EPIC trial results will be dooms day for the company.
I've paid attention to stocks in the pharmaceutical space for some time, following several trials in the process. One thing that I've noticed is that when results are overwhelmingly positive, or overwhelmingly negative for that matter, they are released relatively quickly. When we see delays is when we see a bit of data in that gray area that's not good or bad, but needs to be defined as black or white. With that said, I'm not expecting for the data released by MSTX to be overwhelmingly positive or overwhelmingly negative. I'm expecting to see results that are somewhere in the middle, but I do expect for the primary endpoint to be met.
What We're Seeing From The Stock Today
At the moment, MSTX is on the downtrend. With uncertainties surrounding the EPIC trial, this is understandable. Currently (12:21), the stock is trading at $0.58 per share after a loss of 1.31% thus far today.
What I'm Expecting To See Moving Forward
Overall, my opinion with regard to Mast Therapeutics is a relatively bullish one. While I understand the concerns revolving around the EPIC trial, if the data was overwhelmingly negative, it would likely have already been released. With that said, I will be patient as the company continues to analyze the data. With regard to the trial, I'm expecting that MSTX has something incredible here, and that the trial results will show that. All in all, while things are taking longer than some would like, the stock is looking more and more like a strong investment option.
http://cnafinance.com/mast-therapeutics-mstx-stock-a-defining-moment-is-just-around-the-corner/11235
Analysts Covering MSTX: Strong buy, Avg. Price Target $3.33
(474.14% Upside)
High
$5.00 762.07% Upside
Avg
$3.33 474.14% Upside
Low
$2.00 244.83% Upside
https://www.tipranks.com/stocks/mstx
Consensus Ratings for MSTX (MartketBeat)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating: Buy (Score: 3.00)
Consensus Price Target: $3.33 (484.90% upside)
9/8/2016 Maxim Group Set Price Target Buy $5.00
+8/1/2016 Roth Capital Reiterated Rating Buy $2.00
+7/28/2016 Canaccord Genuity Reiterated Rating Buy $3.00
https://www.marketbeat.com/stocks/NASDAQ/MSTX/?added
Research Reports on Biotech Equities -- Galena Biopharma, Mast Therapeutics, Medivation, and Amgen
07:35 ET from Chelmsford Park SA
The Biotech industry registered strong gains on Monday, September 12, 2016, with every ETF in the green. Driving stocks higher were surges in M&A deals, dovish comments made by the Fed on policy tightening, and Trump's rising tracking poll results. Today, Stock-Callers.com reviews four equities to see how they fared over the last few trading sessions: Galena Biopharma Inc. (NASDAQ: GALE), Mast Therapeutics Inc. (NYSE MKT: MSTX), Medivation Inc. (NASDAQ: MDVN), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free research reports at: http://stock-callers.com/registration
Galena Biopharma
San Ramon, California-based Galena Biopharma Inc.'s shares gained 0.82%, closing Thursday's trading session at $0.33. The stock recorded a trading volume of 4.21 million shares. Shares of the Company are trading 22.52% below their 50-day moving average. Additionally, shares of Galena Biopharma, which focuses on developing and commercializing oncology therapeutics that address major unmet medical needs, have a Relative Strength Index (RSI) of 33.40.
On September 12th, 2016, Galena Biopharma announced the issuance of a second Japanese Patent containing composition and method of use claims for GALE-401, the Company's controlled release version of anagrelide. The patent covers the treatment of patients suffering from myeloproliferative diseases, including myeloproliferative neoplasms such as essential thrombocythemia and polycythemia vera. The patent provides GALE-401 exclusivity until 2029, not including any patent term extensions. Free research report on GALE is available at: http://stock-callers.com/registration/?symbol=GALE
Mast Therapeutics
On Thursday, shares in San Diego, California headquartered Mast Therapeutics Inc. recorded a trading volume of 7.58 million shares, which was above their three months average volume of 4.21 million shares. The stock edged 15.20% higher, ending the day at $0.57. The Company's shares have surged 35.69% in the last month, 32.53% in the previous three months, and 35.69% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 31.10% and 52.51%, respectively. Furthermore, shares of Mast Therapeutics, which develops therapies for serious or life-threatening diseases with significant unmet needs, have an RSI of 59.82.
On September 6th, 2016, Mast Therapeutics announced that it is joining other industry leaders, patient advocacy groups, researchers, clinicians, policymakers, and foundations in a collective effort to improve sickle cell disease (SCD) care, early diagnosis, treatment, and research both in the US and globally. SCD is an inherited, lifelong disorder characterized by red blood cells that become rigid and sickle-shaped, which causes them to stick together and block the flow of oxygen to the body, leading to intense pain and other serious issues such as stroke, organ failure, and death. SCD affects approximately 100,000 Americans and millions worldwide. The complimentary research report on MSTX can be downloaded at: http://stock-callers.com/registration/?symbol=MSTX
Medivation
San Francisco, California headquartered Medivation Inc.'s stock finished the day 0.09% lower at $81.05. A total volume of 5.64 million shares was traded, which was above their three months average volume of 3.82 million shares. The Company's shares have gained 24.27% in the last one month, 36.54% in the previous three months, and 67.67% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 16.94% and 55.19%, respectively. Additionally, shares of Medivation, which focuses on the development and commercialization of medical therapies to treat serious diseases in the US, have an RSI of 87.68.
On August 22nd, 2016, Pfizer Inc. and Medivation announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation for $81.50 a share in cash for a total enterprise value of approximately $14 billion. The Boards of Directors of both companies have unanimously approved the merger.
On August 23rd, 2016, research firm Stifel downgraded the Company's stock rating from 'Buy' to 'Hold'. Visit us today and access our complete research report on MDVN at: http://stock-callers.com/registration/?symbol=MDVN
Amgen
Shares in Thousand Oaks, California headquartered Amgen Inc. ended yesterday's session 1.47% higher at $172.64. The stock recorded a trading volume of 2.92 million shares. The Company's shares have advanced 0.28% in the last one month, 14.01% over the previous three months, and 8.42% on an YTD basis. The stock is trading 2.45% above its 50-day moving average and 10.87% above its 200-day moving average. Moreover, shares of Amgen, which engages in discovering, developing, manufacturing, and delivering human therapeutics worldwide, have an RSI of 56.76.
On August 26th, 2016, research firm Gabelli & Co. initiated a 'Hold' rating on the Company's stock.
On September 15th, 2016, Amgen announced detailed global Phase 2 results showing erenumab demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. In an analysis of exploratory endpoints, both doses of erenumab were associated with significant improvements in health-related quality of life, headache impact, disability, and level of pain interference, compared to placebo. Get free access to your research report on AMGN at: http://stock-callers.com/registration/?symbol=AMGN
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
The Biotech industry registered strong gains on Monday, September 12, 2016, with every ETF in the green. Driving stocks higher were surges in M&A deals, dovish comments made by the Fed on policy tightening, and Trump's rising tracking poll results. Today, Stock-Callers.com reviews four equities to see how they fared over the last few trading sessions: Galena Biopharma Inc. (NASDAQ: GALE), Mast Therapeutics Inc. (NYSE MKT: MSTX), Medivation Inc. (NASDAQ: MDVN), and Amgen Inc. (NASDAQ: AMGN). Learn more about these stocks by accessing their free research reports at: http://stock-callers.com/registration
http://www.prnewswire.com/news-releases/research-reports-on-biotech-equities----galena-biopharma-mast-therapeutics-medivation-and-amgen-593674671.html
MSTX:Consensus recommendation: Buy:1 Outperform 5
Share price forecast
The 4 analysts offering 12 month price targets for Mast Therapeutics Inc have a median target of 2.50, with a high estimate of 5.00 and a low estimate of 1.00. The median estimate represents a 405.36% increase from the last price of 0.4947.
High 910.7% 5.00
Med 405.4% 2.50
Low 102.1% 1.00
http://markets.ft.com/data/equities/tearsheet/forecasts?s=MSTX:ASQ
(NYSE:X) Given Consensus Rating of “Hold” by Analysts
Posted by Jared Coughlin on Sep 14th, 2016 //
Shares of United States Steel Corp. (NYSE:X) have been given a consensus rating of “Hold” by the twenty-two brokerages that are currently covering the company. Five equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $21.91.
Several research firms have recently commented on X. Morgan Stanley reissued a “hold” rating and issued a $19.00 target price on shares of United States Steel Corp. in a report on Thursday, July 28th. Axiom Securities reissued a “sell” rating on shares of United States Steel Corp. in a report on Monday, May 23rd. Zacks Investment Research downgraded shares of United States Steel Corp. from a “buy” rating to a “hold” rating in a report on Monday, August 8th. Barclays PLC reissued an “equal weight” rating and issued a $16.00 target price (up previously from $15.00) on shares of United States Steel Corp. in a report on Tuesday, July 12th. Finally, Vetr raised shares of United States Steel Corp. from a “strong sell” rating to a “sell” rating and set a $21.70 target price on the stock in a report on Tuesday, August 9th.
Shares of United States Steel Corp. (NYSE:X) traded down 0.49% during midday trading on Wednesday, reaching $16.27. 11,031,318 shares of the company’s stock were exchanged. United States Steel Corp. has a 12-month low of $6.15 and a 12-month high of $27.64. The firm has a 50-day moving average of $21.86 and a 200-day moving average of $18.02. The stock’s market capitalization is $2.39 billion.
United States Steel Corp. (NYSE:X) last issued its quarterly earnings results on Tuesday, July 26th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.18. United States Steel Corp. had a negative net margin of 15.09% and a negative return on equity of 20.96%. The business had revenue of $2.58 billion for the quarter, compared to the consensus estimate of $2.68 billion. During the same quarter in the previous year, the firm earned ($0.79) earnings per share. The company’s revenue for the quarter was down 10.9% on a year-over-year basis. Analysts anticipate that United States Steel Corp. will post ($0.72) EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Saturday, September 10th. Investors of record on Wednesday, August 10th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 1.22%. The ex-dividend date was Monday, August 8th. United States Steel Corp.’s dividend payout ratio (DPR) is presently -1.88%.
A number of hedge funds have recently added to or reduced their stakes in the company. Amerigo Asset Management purchased a new stake in United States Steel Corp. during the first quarter valued at approximately $70,399,000. Anchor Bolt Capital LP raised its stake in United States Steel Corp. by 473.2% in the second quarter. Anchor Bolt Capital LP now owns 4,694,947 shares of the company’s stock valued at $79,157,000 after buying an additional 3,875,834 shares during the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in United States Steel Corp. during the first quarter valued at approximately $41,730,000. Allianz Asset Management AG raised its stake in United States Steel Corp. by 361.3% in the second quarter. Allianz Asset Management AG now owns 2,795,482 shares of the company’s stock valued at $47,132,000 after buying an additional 2,189,432 shares during the last quarter. Finally, Impala Asset Management LLC raised its stake in United States Steel Corp. by 192.5% in the second quarter. Impala Asset Management LLC now owns 2,854,325 shares of the company’s stock valued at $48,124,000 after buying an additional 1,878,547 shares during the last quarter. 63.56% of the stock is owned by institutional investors.
United States Steel Corp. Company Profile
United States Steel Corporation (U. S. Steel) is an integrated steel producer. The Company is engaged in producing flat-rolled and tubular products with production operations in North America and Europe. The Company operates through three segments: Flat-Rolled Products (Flat-Rolled), U. S. Steel Europe (USSE) and Tubular Products (Tubular).
http://www.com-unik.info/2016/09/14/united-states-steel-corp-nysex-given-consensus-rating-of-hold-by-analysts-2.html
USITC Finds Injury in Hot-Rolled Steel Case, Affirms Duties
The U.S. International Trade Commission (“USITC”) has made its final determinations on anti-dumping and countervailing duty investigations on imports of certain hot-rolled steel flat products by seven countries into the American market. Hot-rolled steel is used in appliances, automotive products, heavy machinery, machine parts, commercial construction and transportation equipment.
The USITC found that imports of these products from Australia, Brazil, Japan, South Korea, the Netherlands and the U.K. as well as imports from Turkey that are sold in the U.S. at less than fair value have caused material injury to the American steel industry. The regulator also affirmed most of the anti-dumping and countervailing duties on imports of these products.
The ruling marks yet another victory for crisis-hit U.S. steel companies in their ongoing battle against unfairly-traded, cheap imports.
The U.S. Department of Commerce ("DOC") earlier determined that these products are being sold in the American market below their fair values and are subsidized by the governments of Brazil, South Korea and Turkey.
The nation’s biggest steel producers, in Aug 2015, filed anti-dumping and countervailing duty petitions with the DOC and the USITC against these seven countries. The petitions, which were filed by six U.S. steel makers including Nucor (NUE - Analyst Report) , U.S. Steel (X - Analyst Report) , AK Steel (AKS - Analyst Report) , Steel Dynamics (STLD - Snapshot Report) and ArcelorMittal USA – a part of ArcelorMittal (MT - Analyst Report) – charge that a torrent of significantly subsidized imports of hot-rolled steel flat products from these nations are causing significant injury to the U.S. steel industry.
Imports of hot-rolled steel from Australia, Brazil, Japan, South Korea, the Netherlands, Turkey and the U.K. were valued at an estimated $122.5 million, $252.6 million, $314.7 million, $649.5 million, $208.4 million, $181.7 million and $197.1 million, respectively, in 2015 (combined value of more than $1.9 billion).
These products are being illegally dumped by foreign steel producers in the American market at unfairly low prices that significantly undercut the prices of U.S. steel makers. These imports have also captured an increasing share of the U.S. market, thereby hurting production, shipments, selling prices and margins of U.S. steel makers.
As a result of the USITC’s affirmative findings, the DOC will now issue countervailing duty orders on imports of hot-rolled steel products from Brazil and South Korea and anti-dumping duty orders on imports from Australia, Brazil, Japan, South Korea, the Netherlands, Turkey and the U.K.
The DOC, last month, slapped a final anti-dumping duty rate of 29.37% on Australian exporters of these products. Brazil’s Usiminas received the highest anti-dumping duty rate of 34.28% while other Brazilian producers were levied final anti-dumping duty of 33.14%. Exporters in the U.K. received anti-dumping duty of 33.06%. Final dumping duties for South Korea and Japan were imposed in the range of 3.89%-9.49% and 4.99% to 7.51%, respectively.
The commerce department also levied final countervailing duty rate in the band of 11.09% to 11.30% on Brazilian producers. In case of South Korea, POSCO and Daewoo International received countervailing duty of 57.04% while other producers were levied a duty of 3.89%.
However, the USITC concluded that imports of hot-rolled steel products from Turkey, which the DOC had determined are subsidized by that country’s government, are negligible. As a result, no countervailing duty order will be issued on imports of these products from Turkey.
The latest ruling comes after the USITC’s affirmative final determination on the cold-rolled steel case, announced earlier this month. The regulator found that imports of cold-rolled steel flat products from Brazil, India, Korea, and the U.K. have caused or threatened to cause material injury to the U.S. steel industry.
U.S. steel companies have been hammered by a tide of cheap imports over the past few years that largely contributed to a slump in steel prices. Low costs of production have allowed overseas producers to sell their products at cheaper rates, leading to an industry-wide price decline.
Nevertheless, steel market conditions in the U.S. have improved of late, driven by favorable developments on steel trade cases in the recent past. Steel prices recovered during the second quarter of 2016, helped by punitive trade actions that led to levy of tariffs on imports. U.S. steel producers continue to actively press the U.S. regulators to stop unfair trade practices and ensure a fairer and more competitive market for American steel makers and workers.
A couple of stocks worth considering in the steel space are ArcelorMittal, sporting a Zacks Rank #1 (Strong Buy) and Ternium S.A. (TX - Snapshot Report) , holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
https://www.zacks.com/stock/news/231305/usitc-finds-injury-in-hotrolled-steel-case-affirms-duties
One Month Ago Analyst Ratings: (NYSE:X)
United States Steel Corporation (NYSE:X) showed bearish move with loss of -6.20% after exchanging volume of 20.32 million shares in last trading session ended on 9/13/2016. The company recent traded volume was higher than its average volume of 15.13 million shares. United States Steel Corporation has an EPS ratio of -11.56. The stock has a consensus analyst price target of $43.54for twelve month. The company finished it is trading at $16.35.
During the 52-week period, the peak price level of the share was observed at $27.64; this is higher price of share and down price level of the share was seen at $6.15; this is lower price at which share is traded.
Present Consensus Recommendation for UNITED STATES STEEL CORPORATION (X): President and CEO Mario Longhi issued the following statement in response to the International Trade Commission (ITC)’s affirmative injury determination regarding hot-rolled steel imports from Australia, Brazil, Japan, the Netherlands, South Korea and the United Kingdom. “It is clear that the International Trade Commission recognized the significance of this case to the domestic industry as demonstrated by its affirmative determination in the hot-rolled steel investigation from Australia, Brazil, Japan, the Netherlands, South Korea and the United Kingdom. We are encouraged that we have received affirmative determinations in the vast majority of the three flat-rolled cases we have filed. This decision is yet another positive step towards establishing a level playing field. We know that there is work yet to be done, and we will continue our efforts to ensure fair trade and adherence to the rule of law.”
UNITED STATES STEEL CORPORATION (X) received consensus recommendation of “Hold” from Analysts polled at Thomson Reuters. The Company expected to announce next earnings approximately $0.91 per share.
One Month Ago Analyst Ratings: The Company has received mean Analyst rating of 3.00 from polled analysts at Reuters One Month Ago. It has been suggested as “Buy Opinions” from 1 and 1 issued “Sell Thoughts” for the stock. 7 rated the company as a “Hold”. “Outperform View” rating was revealed by 4 and “Underperform Signal” rating was issued by 4.
Sales Estimates: Wall Street Analysts are estimating average sales of $2,841.19M for current quarter (Quarter Ending Sep-16). Analysts projected the minimum sales estimate of $2,731.00M and some analysts told that the stock may achieve maximum sales of $2,934.00M. Average sales estimate is measured after the consensus analysis of 9 Analysts.
http://www.streetupdates.com/2016/09/14/one-month-ago-analyst-ratings-united-states-steel-corporation-nysex/
The X Paradox: Analysts Bearish But Forecast 14.26% Gains
http://www.forbes.com/sites/dividendchannel/2016/09/14/the-x-paradox-analysts-bearish-but-forecast-14-26-gains/#7c48aa62173e
?
?
?
?
?
U.S. Steel: More Tariffs But Stock Clobbered Anyway -- Barron's Blog
10:52 am ET September 13, 2016 (Dow Jones)
By Ben Levisohn
U.S. Steel ( X) got what it wanted when the U.S. International Trade Commission ruled that seven countries could be hit with tariffs for dumping their steel. Citigroup's Alexander Hacking has the details:
Hot Rolled Coil Steel - The ITC has confirmed final duties on HRC imports from seven countries: Australia, Brazil, Japan, Korea, the Netherlands, the UK and Turkey (dumping only). Note: China has already been ruled against. Import duties are now fixed for five years. The only blip is that the ITC made a negative ruling on Turkish government subsidies (so the duty now applies to anti-dumping only at 4-7%, removing the additional 6% subsidy rate). Platts reports that one Turkish mill has been offering sales with the duty paid.
Stainless - The DoC yesterday made a preliminary determination that imports of stainless steel from China are being sold at dumping prices in the US. Preliminary duties have been established at 64% to 77%. The ITC will now investigate damages to domestic producers before determining final duties.
These two rulings were widely expected but continue t he positive momentum of US steel producers in widening trade protection. We expect domestic U.S. steel prices to hold the $550-600/t range in 2H16, partly supported by lower imports and also by low inventory and mill idlings. Prices are expected to fall to $500-550/t in mid-2017 as traders find new sources of imports.
Unfortunately, the rulings have done nothing for U.S. Steel's stock--or the stocks of competitors like AK Steel ( AKS), Nucor ( NUE) and Steel Dynamics ( STLD)--today.
Shares of U.S. Steel have dropped 5.2% to $16.53 at 10:49 a.m. today, while AK Steel has tumbled 5.6% to $4.02, Nucor has fallen 2.6% to $46.46, and Steel Dynamics is off 2.6% to $23.50.
More at Barron's Stocks to Watch blog, http://blogs.barrons.com/stockstowatchtoday/
(END) Dow Jones Newswires